Surface molecule volumes flowing through UNICEF, Global Fund, and MoH institutional channels. Size the tender market against commercial demand.
Dolutegravir's institutional procurement footprint sits at $10.1M across 57 shipments and 6 destinations with Mozambique ($5.83M) and Zimbabwe ($3.02M) leading. Amoxicillin's footprint runs through the UNICEF Copenhagen hub at $10.8M across 716 shipments and 10 destinations. Paracetamol, albendazole, and measles vaccine round out the top tier of institutional pharmaceutical procurement signal in the warehouse.
| # | Molecule | Top destination | Institutional value | Shipments | Destinations |
|---|---|---|---|---|---|
| 1 | Dolutegravir | MZ + ZW + others | 57 shipments | $10.1M | NAI |
| 2 | Amoxicillin | DK hub + SO + 8 | 716 shipments | $10.8M | VAI |
| 3 | Paracetamol | DK + YE + 7 | 421 shipments | $3.95M | NAI |
| 4 | Albendazole | DK + 3 | 83 shipments | $2.75M | NAI |
| 5 | Measles vaccine | NG + AF + 1 | 12 shipments | $3.35M | NAI |
A single molecule, a class (antiretrovirals, antibiotics), or the full institutional cohort. The procurement_flows table covers UNICEF, Global Fund, MoH tenders, and similar channels.
Institutional value, shipment count, destination count, and the institutional-versus-commercial split. Computed at the warehouse layer against molecule_country_flow.
Citation-anchored brief with the destinations, the shipment cadence, and a recommended tender or WHO-PQ priority list.
Dolutegravir's $10M institutional footprint is small in absolute terms but heavy in policy weight. Most blockbusters look bigger commercially but the tender channel still drives the price floor.
Denmark recurs as a destination for amoxicillin, paracetamol, albendazole. That's the UNICEF Copenhagen hub. The brief flags it so a tender team reads the destinations correctly.
Molecules with growing institutional flow are WHO-PQ candidates. The AI agent ranks them by year-on-year institutional momentum.
Amoxicillin shows 0.71% institutional share against $415M commercial. Dolutegravir is heavier on the institutional side. Different tender plays, different price floors.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecules with observable institutional flow · count is shipments per molecule across the catalog · institutional channel only.
The institutional procurement view is the tender-market sizing signal on top of the commercial trade flow. PharmaDB joins procurement_flows to molecule_country_flow, surfaces the destinations, and returns a commercial-versus-institutional split per molecule. The view is procurement_flows; the join is to the molecule catalog.
Aggregated procurement flows visible in the public procurement_flows feed: UNICEF Supply Division, Global Fund procurement, country MoH tenders, and similar institutional channels. Commercial trade is excluded; that signal is the molecule_country_flow view.
Denmark is the UNICEF Copenhagen supply hub. Most antibiotic and antiparasitic flows route through it before redistribution. The brief surfaces it as a hub destination rather than a commercial endpoint.
Median institutional-versus-commercial share for blockbuster molecules sits below 1%. Categories with strong institutional weight (antiretrovirals, antibiotics, antiparasitics) can hit 10% or higher. The split is computed inline.
The institutional channel is structurally less observable than the commercial one. The 480 rows in procurement_flows cover the major institutional flows but smaller MoH tenders are under-represented. Treat it as a directional signal, not a complete inventory.
Molecules with growing institutional flow and no current WHO-PQ are flagged as WHO-PQ priority. Holders of WHO-PQ status get a different tender-eligibility chip on the result.
Procurement flows refresh monthly. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.